Ongoing Clinical Trials for Eye Pain
This article provides information about ongoing clinical trials investigating treatments for eye pain, specifically focusing on inflammation and discomfort following eye surgery in young children. Currently, there is 1 active clinical trial examining new approaches to managing post-surgical eye pain and inflammation.
Clinical trial locations
Study on Clobetasol Propionate and Prednisolone Acetate for Treating Eye Inflammation After Cataract Surgery in Children Aged 0-3 Years
This clinical trial is being conducted in Spain and focuses on treating inflammation and pain that occurs after cataract surgery in very young children, specifically those between birth and 3 years of age. The study compares two different types of eye drop medications to determine which is safer and more effective for managing post-surgical inflammation.
Main inclusion criteria: Children eligible for this study must be between 0 and 3 years old and scheduled for routine cataract surgery in one eye. After the surgery, they must show clinical signs of inflammation, such as swelling or irritation in the front part of the eye. The child’s parents or legal guardians must be willing and able to follow all treatment instructions and attend all follow-up visits. Written informed consent from the parents or legal representatives is required before the child can participate in the study.
Main exclusion criteria: Children cannot participate if they have other eye conditions that might affect the study results or if they have had recent eye surgery beyond the cataract procedure. Those who are allergic to any of the medications being tested are excluded. Children taking other medications that could interfere with the study treatments, those with serious health conditions that might affect participation, or those unable to follow study instructions cannot take part. Additionally, children already participating in another clinical trial at the same time are not eligible.
Focus and goals: The primary goal of this trial is to assess the safety of two different anti-inflammatory eye drop treatments in young children who have undergone cataract surgery. The study follows a structured timeline with multiple follow-up visits. After surgery and enrollment, children are randomly assigned to receive either Clobetasol propionate ophthalmic nanoemulsion at 0.05% concentration or Prednisolone acetate ophthalmic suspension at 1% concentration. The children are then monitored through five scheduled visits over approximately six weeks. During these visits, doctors assess inflammation levels, measure pressure inside the eye, and monitor for any side effects or changes in eye health. The study aims to determine which treatment is more effective at reducing inflammation and pain while being safe for this vulnerable age group.
Investigational drugs: The trial tests Clobetasol propionate ophthalmic nanoemulsion, 0.05%, which is an experimental eye drop formulation designed to reduce inflammation. This medication belongs to a class of drugs called corticosteroids, which work by preventing the release of substances in the body that cause inflammation. It is still under investigation and not yet widely used in standard medical practice for this specific indication. The second medication being tested is Prednisolone acetate ophthalmic suspension, 1%, which is a well-established corticosteroid eye drop commonly used to manage inflammation and pain after eye surgery. It works by suppressing the immune response that leads to swelling and discomfort. Both medications are administered as eye drops, and the study compares their safety and effectiveness in treating post-surgical inflammation in very young children.
Summary
Currently, there is one ongoing clinical trial specifically addressing eye pain related to post-surgical inflammation in young children. This trial is being conducted in Spain and focuses exclusively on children aged 0 to 3 years who have undergone cataract surgery. The study compares an experimental corticosteroid formulation (Clobetasol propionate nanoemulsion) with a standard treatment (Prednisolone acetate suspension) to determine which is safer for this vulnerable population. The trial emphasizes safety assessment rather than just effectiveness, which is particularly important given the young age of the participants. Both medications being tested belong to the corticosteroid family and work by reducing inflammation, though they differ in their specific formulation and established use in medical practice.
